Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation

Currently, there are four CAR-T products commercially available on the market. CAR-T cells have shown high remission rates and they represent an effective treatment option for patients with resistant or refractory B cell malignancies. Approval of these cell therapy products came after an extended pe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Virginia Picanço-Castro, Martín Hernan Bonamino, Rodrigo Nalio Ramos, Renato L. Guerino-Cunha, Theo Gremen M. Oliveira, Eduardo M. Rego
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/ad7835ecd3b342c4b49161e3aaa1bacf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!